Abstracts Archive - Page 415 of 1683 - ATC Abstracts

2020 American Transplant Congress
Immune Cell Subset Profiles in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts) Desensitized with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Followed by Transplantation (Tx)
S. Ge¹, M. Chu¹, A. D. Guzman¹, E. D. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: IL-6, B cell growth factor, increases follicular T helper cell (Tfh) activity, promoting plasmablast (PB) and plasma cell (PC) differentiation, and antibody production. A…
2020 American Transplant Congress
Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy
C. M. Castro-Rojas¹, S. Tremblay², J. Driscoll³, K. Roskin⁴, R. R. Alloway³, E. Woodle², D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, ³Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
*Purpose: Patients sensitized to HLA antigens by prior transplantation, pregnancy or blood transfusion may have markedly prolonged waiting times for transplant. Moreover, once transplanted, the…
2020 American Transplant Congress
Quantitative Analysis of Humoral Immunity by Flow-Cytometric Crossmatch Using Molecules of Equivalent Soluble Fluorochromosome (FCXM-MESF)
H. Ishida, M. Furusawa, T. Shimizu, M. Okumi, Y. Kakuta, K. Omoto, K. Tanabe
Tokyo Womens, Tokyo, Japan
*Purpose: In this study, we examined the quantitative significance of humoral immunity by flow-cytometric crossmatch using molecules of equivalent soluble fluorochromosome (FCXM-MESF) in recipients of…
2020 American Transplant Congress
Prevalence of Kidney Transplant-Associated Thrombotic Microangiopathy after ABO-Incompatible Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Thrombotic microangiopathy (TMA) is a dangerous disorder characterized by fragmented red blood cells, decreased platelet count, and organ failure due to thrombosis. We investigated…
2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
I. Revuelta¹, E. De Sousa-Amorim¹, M. Lozano², D. Cucchiari¹, J. Cid², L. Peri³, E. Palou⁴, M. Musquera³, J. Martorell⁵, J. M. Campistol¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, ²Apheresis and Cellular Therapy Unit, Hospital Clinic, Barcelona, Spain, ³Department of Urology, Hospital Clinic, Barcelona, Spain, ⁴Histocompatibility Lab. Department of Immunology, Hospital Clinic, Barcelona, Spain, ⁵Histocompatibility Lab, Department of Immunology, Hospital Clinic, Barcelona, Spain
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6) Induces Foxp3+ Tregs in Highly HLA Sensitized Patients Desensitized for HLAi Transplantation (NCT03380962)
S. C. Jordan, S. Ge, N. Ammerman, M. Toyoda, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamson, C. Myers, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, West Hollywood, CA
*Purpose: Interleukin-6 is an important inflammatory cytokine. In addition, it acts as a growth factor for B-cells, plasma cells and Th17 cells, inhibiting FoxP3+ Treg…
2020 American Transplant Congress
Peritoneal Dialysis in Delayed Graft Function, a Safe and Effective Option
A. Gardezi, B. Muth, F. Aziz, N. Garg, M. Mohamed, A. Djamali, D. Mandelbrot, S. Parajuli
University of Wisconsin, Madison, WI
*Purpose: Peritoneal dialysis (PD) has been utilized increasingly in the past decade. Many of these patients undergo transplantation and may require dialysis for delayed graft…
2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
B. Shin, N. Ammerman, S. Sethi, A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…
2020 American Transplant Congress
Outcomes of Post-Transplant Desensitization in High Immunological Risk Deceased Donor Kidney Transplant Recipients
D. Kumar, C. Song, L. Kamal, I. Moinuddin, M. Levy, C. Bhati, A. King, P. Kimball, G. Gupta
Virginia Commonwealth University, Richmond, VA
*Purpose: The kidney allocation system (KAS) was changed in 2015 to increase access to transplants for highly sensitized patients. However, recent data suggests that even…
2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
M. J. Moritz¹, D. R. Stevens², U. Meier-Kriesche², T. A. Horwedel²
¹Department of Surgery, Lehigh Valley Health Network, Allentown, PA, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…